Clinical evaluation of safety and efficacy of a new topical treatment for onychomycosis

Journal of Drugs in Dermatology

Volumn 10, Issue 10, 2011, Pages 1186-1191

  Nasir, Adnan ^a   Goldstein, Beth ^b   Van Cleeff, Martin ^c   Swick, Lance ^d  

^a WAKE RESEARCH ASSOCIATES   (United States)

^b Central Dermatology Center   (United States)

^c Cary Medical Research   (United States)

^d Chesson Laboratory Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; POTASSIUM HYDROXIDE;

ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DERMATOLOGICAL PROCEDURES; DRY SKIN; EPIDERMOPHYTON INFECTION; EXPERIMENTAL THERAPY; FEMALE; FUNGUS CULTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAIL COLOR; NONHUMAN; ONYCHOMYCOSIS; PATIENT SAFETY; SELF CARE; TOENAIL ONYCHOMYCOSIS; TREATMENT DURATION; TREATMENT RESPONSE; TRICHOPHYTON MENTAGROPHYTES INFECTION; TRICHOPHYTON RUBRUM INFECTION; TRICHOPHYTON TONSURANS INFECTION;

ADMINISTRATION, TOPICAL; ADULT; AGED; BIOCOMPATIBLE MATERIALS; EPIDERMOPHYTON; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ONYCHOMYCOSIS; POLYMERS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRICHOPHYTON; YOUNG ADULT;

EID: 80054773230     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43(4):641-648.
2. Scher RK, Tavakkol A, Sigurgeirsson B, et al. Onychomycosis: Diagnosis and definition of cure. J Am Acad Dermatol. 2007;56(6):939-944.
3. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166(5-6):353-367. Epub May 14, 2008.
4. Penlac [package insert]. Berwyn, PA: Dermik Laboratories - A Division of Aventis Pharmaceuticals; 2005.
5. Gupta AK, Chwetzoff E, Del Rosso J, et al. Hepatic safety of itraconazole. J Cutan Med Surg. 2002;6(3):210-213. Epub April 15, 2002.
6. Oyeka and Ugwu. Fungal flora of human toe webs. Mycoses. 2002;45(11-12):488-491.
7. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf. 2000;22(1):33-52.
8. Mailland F, Baran R. Sensitivity of Trichophyton rubrum versus other dermatophytes to ciclopirox nail lacquers in patients with onychomycosis. J Am Acad Derm. 2008;58(2):AB90-AB90 Suppl.
9. Romero-Cerecero O, Zamilpa A, Jiménez-Ferrer JE, et. al. Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative clinical trial with ciclopirox. Planta Med. 2008;74(12):1430-1435. Epub July 31, 2008.
10. Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia. 2008;166(5-6):335-352. Epub May 14, 2008.
11. Foster KW; Ghannoum MA; Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50(5):748-752.
12. Tietz HJ, Kunzelmann V, Schönian G. Changes in the fungal spectrum of dermatomycoses. Mycoses. 1995;38(suppl 1):33-39.
13. Lilly KK, Koshnick RL, Grill JP, et. al. Cost-effectiveness of diagnostic tests for toenail onychomycosis: A repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests. J Am Acad Dermatol. 2006;55(4):620-626. Epub June 13, 2006.